Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models

Figure 6

EBC-46 causes disruption and permeability of endothelial cells within tumor.

A. Immunohistochemical analysis of CD31 staining of FaDu head and neck cancer tumors treated with EBC-46. FaDu tumors were allowed to reach 100 mm3 before they were treated with either vehicle (20% propylene glycol in water) or 50 nmol (30 µg) EBC-46, and harvested at the indicated times. Representative photomicrographs are shown of the tumor site. Black arrows – examples of vessels with compromised or disrupted structural integrity. Scale bars = 100 µm. B. Monolayers of HUVEC cells were treated with 350 µM (200 µg/ml) EBC-46 for 30 mins, before being assessed for permeability to FITC labeled Dextran. (***, p = 0.0013; t-test). C. HUVEC cells were treated with 350 µM (200 µg/ml) EBC-46 for 30 mins with or without 5 µM bisindolylmaleimide-1, before being assessed by propidium iodide exclusion. Error bars – SD, n = 3.

Figure 6